Tramadol IV Opioid Gets Negative Vote From US FDA Advisory Panel

 
• By Brenda Sandburg
  
Tramadol
Joint US FDA advisory committee concludes data do not show the benefits of tramadol IV outweigh its risks. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers